García VM, Encampira NBA, Luna PLA, Akaki BJL

Language: Spanish
References: 26
Page: 21-23
PDF size: 777.28 Kb.

ABSTRACT

Background: In obese patients with metabolic syndrome are decreased serum concentrations of vitamin D, the intra-abdominal fat deposition favors this and hypovitaminosis.
Objective: To document the insulin resistance through measurement of fasting insulin and glucose that allow for and value equation HOMA insulin sensitivity for subsequent statistical testing of correlation between vitamin D status and resistance to insulin in obese population of Juarez Hospital of Mexico.
Patients and methods: Prospective, cross sectional, descriptive, open, experimental performed in patients who agreed to participate in the study protocol, after receiving detailed information about the purpose of the study patients were recruited from the outpatient internal medicine among March and June 2009 with the inclusion and exclusion criteria.
Results: We diagnosed 19 (63.3%) patients with metabolic syndrome according to ATP III criteria, 7 (23.3%) women and 12 (40%) men and 11 (36.7%) only with obesity, 10 (33.3% ) women and 1 (3.3%) men, who were compared with a control group of five healthy subjects with adequate height and weight and BMI less than 25.
Conclusions: This work was conducted in order to know the status of vitamin D in the Hispanic population with an initial diagnosis of obesity. Important was the finding that a high percentage of patients who were obese only considered the defining criteria for metabolic syndrome.

REFERENCES

1. Bruce WH. Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Current Opinion in Endocrinology, Diabetes and Obesity 2008;15:489-94.

2. Marazuela M. Déficit de vitamina D en el adulto: clínica, diagnóstico y tratamiento. Revista de Endocrinología y Nutrición 2005; 52(5):215-23.

3. Dawson-Hughes B, et al. Estimates of optimal vitamin D status. Osteoporosis International 2005;16:713-716.

4. Harbans Lal, Rajesh Pandey, et al. Vitamin D: Actions for the new millennium. Indian Journal of Clinical Biochemistry2000; 15(Suppl):158-68.

5. Christakos S, et al. New insigths into the mechanisms of vitamin D action. J Cell Biochem 2003;88:6695-705.

6. Holick M. Vitamin D deficiency in obesity and health consequences. Current Opinion in Endocrinology, Diabetes and Obesity 2006;13:412-18. Figura 7. Muestra los valores de vitamina D3 expresados en nano gramos en comparación con el grupo control.

7. Rammos G, Tseke P, et al. Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol 2008; 40: 419-442.

8. Flores M, Barquera S. Vitamina D y diabetes. Nutrición Clínica 2004;7 (3):180-4.

9. Ken C Chiu, Audrey Chu et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79:820-5

10. Zamora Valdés; Mecanismos moleculares de resistencia a la insulina. Revista de la Asociación Médica Sur 2004, 11 (3) Julio-Septiembre 2004.

11. Vázquez Chávez, C. ¿Cuál es el nivel de insulina en una población mexicana en peso ideal?. Revista de Endocrinología y Nutrición 2003; 11(1):22-7.

12. Zamora GJ, et al. Clustering of metabolic disorders and hyperinsulinemia in Mexico City. International Journal of Obesity 1996; 20:311-18.

13. Walton C, et al. Effect of body mass index and fat distribution on insulin sensivity, secretion and clearance in non-obese healthy men. J Clin Endocrinol Metab 1992; 75:170-5.

14. Park YW, et al. The metabolic syndrome: prevalence and associated risk factors findings in US population from the third national health and nutrition examination survey. Arch Intern Med 2003; 163:427-36.

15. Lerman, Israel et al. Características del síndrome metabólico en México. Revista de Endocrinología y Nutrición, 2004; 12(3):109-22.

16. González A et al. Consenso Mexicano sobre el tratamiento integral del síndrome metabólico. Rev Mex Cardiol 2002; 13(1):4-30.

17. Gómez, Francisco et al. Posición de la SMNE sobre el manejo del síndrome metabólico. Revista de Endocrinología y Nutrición 2005;13(1):9-23

18. Meigs, J; Definitions and mechanisms of the metabolic syndrome. Current Opinion in Endocrinology and Diabetes 2006; 13:103-10.

19. Agoston-Coldea, Lucia et al. The correlation between metabolic syndrome parameters and heart failure severity in patients with prior myocardial infarction. Acta Endocrinológica Buc 2008; IV(3):251-61.

20. Mathieu C, et al. Vitamin D and Diabetes. Diabetología 2005; 48:1247-57.

21. Pittas A, Lau J. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92(6):2017-29.

22. Bell NH, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;7:690-3

23. Shi H, et al. 1 Alpha, 25-dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J 2001;15:2751-3.

24. Botella-Carretero, J et al. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clinical Nutrition 2007;26:573-80.

25. Khajehdehi P, et al. Effect of oral calcitriol pulse therapy on the lipid, calcium and glucose homeostasis of hemodialysis patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 2003;13:78-83.

26. Major GC; et al. Supplementation with calcium + vitamin D enhaces the beneficial effect of weigth loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007; 87:54-9.